Frontlight ResearchEarly access
Not yet recruitingPhase 3
RASBU-SEPSIS Study: Effects of rasburicase on kidney during sepsis – a randomized, placebo-controlled, double-blind trial
Key facts
- Who runs it
- Assistance Publique Hopitaux De Paris
- Where
- France6 sites in 1 countryChoose a country to see its sites
- Trial code
- Status
- Not yet recruiting
- Phase
- Phase 3
- People taking part
- 240 people, planned
- Started
- 1 Dec 2025
- Expected to end
- 1 Mar 2029
- Type of study
- Interventional
- Record updated
- 15 September 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 21 criteriaShow less
Who can take part
- Patients ≥18 years old
- Diagnosis of sepsis (presumed or known infection and increase in SOFA score ≥ 2), included within 48 hours of diagnosis
- Uricémia ≥ 200 µmol/L
- Rapid diagnostic test strip for G6PD deficiency negative
- Patient affiliated with a social security scheme
- Informed consent form signed
- Woman of childbearing age using effective contraception throughout the treatment and for 1 month after the end of the treatment
- Hospitalised in intensive care unit
Who cannot take part
- Chronic treatment with a urate-lowering agent
- Surgery involving the kidneys or urinary tract in the last 3 months
- Other metabolic disorders known to cause hemolytic anemia
- Chronic kidney failure on hemodialysis
- Known hypersensitivity to Rasburicase, or to any of the excipients,
- Pre-existing condition or situation at risk of lysis syndrome
- Minor
- Enrolled in another
- Sepsis due to urinary obstruction
- Life expectancy less than 6 months
- Pregnant or breastfeeding woman
- AKI with need for dialysis treatment estimated within 12 hours
- Known G6PD deficiency or suggestive family history
Where is this trial?
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
Determine the effect of Rasburicase on the occurrence and evolution of acute renal failure (ARF) in septic patients with uricemia ≥200 µmol/L.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Official title
- RASBU-SEPSIS Study: Effects of rasburicase on renal function during sepsis – a randomized, placebo-controlled, double-blind trial
- Record updated
- 15 September 2026